Very impressive review of Brilacin and its potential anti viral and specifically its anti coronal virus effects. It is easy to see why researchers want to urgently test Brilacidin in hopes of stemming the epidemic.
Most reports show the fatalities are due to respiratory failure which would include direct viral pneumonia plus secondary bacterial infection.In addition reports note severe pulmonary inflammation and fibrosis complicating the infection and resulting in respiratory failure and requiring mechanical ventilation.
Brilacidin's antibiotic, anti inflammatory and now possible antiviral effects seem to be ideal to combat the pulmonary effects of coronavirus.
The mechanism of it viral action seems to be the same as its bacterial mechanism of action. Brilacidin attaches to the bacterial cell wall and the viral protein coat which results in their lysis and subsequent destruction.
Brilacidin's anti inflammatory effects would help combat the excessive inflammation and scarring which results in blockage of the air sacs [aveoli] and small airways[bronchi] and ends in respiratory failure.
For IPIX this is a no risk venture. At a minimum Brilacidin is going to receive intensive and expensive study. At best it will be shown to be an important therapeutic to combat the corona virus epidemic.
My guess is the optimal therapy will include an antiviral plus an agent or agents {which could be Brilacidin} which would have an anti inflammatory and antibiotic effect. Brilacidin could be given as an IV dose early in the disease to prevent respiratory failure. As I recall its biologic effect is a number of days. Then it could be repeated later if needed.
Leo should be applauded for putting together this professional review. I have been trying to research these items all week and have only had partial success.
Another guess is the labs will complete their in vitro Brilacidin studies quickly. If they confirm Polymedix's early preclincal studies showing Brilacidin is effective against Coronavirus we will see a greatly accelerated FDA phase 3 study which will be done on a worldwide emergent basis at no cost to IPIX.
All the above is in my opinion only. It is an exciting time for IPIX and Brilacidin. We should know in a few weeks how things work out.
Market Data 
Markets 
AI
